US Patent

US12144889 — Methods of treating allergic conjunctivitis

Method of Use · Assigned to Ocular Therapeutix Inc · Expires 2041-04-26 · 15y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a sustained release biodegradable intracanalicular insert for treating allergic conjunctivitis.

USPTO Abstract

Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel. The insert is administered to a subject for the treatment of allergic conjunctivitis.

Drugs covered by this patent

Decadron (dexamethasone) · Generic (originally Merck)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1680`	—	Decadron

Patent Metadata

Patent number: US12144889
Jurisdiction: US
Classification: Method of Use
Expires: 2041-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Ocular Therapeutix Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.